Literature DB >> 6258623

Angiotensin-converting enzyme and its association with outcome in lung cancer.

F K Rømer.   

Abstract

Serum angiotensin-converting enzyme (SACE) in 141 patients with newly detected primary lung cincer was 22.1 +/- 6.1 nmol/ml/min (mean +/- s.d.); lower than in healthy controls (24.4 +/- 6.2 nmol/ml/min, P less than 0.02). No correlation was found between SACE and sex, age, site of cancer, histological type, or lung function. After subdivision of the patients according to increasing SACE levels: less than 16.0 (mean SACE of lung cancer--s.d.), 16.0-22.0, 22.1-28.2 and greater than 28.2 nmol/ml/min (mean SACE of lung cancer + s.d.) there was a strong association (P less than 0.001) between SACE level and the proportion of patients who were radically operated without relapse during 8-22 months follow-up. None of 23 patients within the lowest SACE range were cured, even though 7 were referred for operation after preoperative examination. In contrast, 10/25 patients (40%) within the highest SACE range were cured. The results suggest that low SACE is associated with poor prognosis in lung cancer, even in patients who are judged as being operable on preoperative evaluation; and measurement of preoperative SACE in lug cancer may be a useful prognostic indicator in this disorder.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6258623      PMCID: PMC2010507          DOI: 10.1038/bjc.1981.21

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis.

Authors:  J Lieberman
Journal:  Am J Med       Date:  1975-09       Impact factor: 4.965

2.  Subcellular localization of pulmonary antiotensin-converting enzyme (kininase II).

Authors:  J W Ryan; U S Ryan; D R Schultz; C Whitaker; A Chung
Journal:  Biochem J       Date:  1975-02       Impact factor: 3.857

3.  Sarcoid reactions in pulmonary neoplasms.

Authors:  P Laurberg
Journal:  Scand J Respir Dis       Date:  1975-05

4.  Increased serum angiotensin converting enzyme activity in sarcoidosis.

Authors:  E Silverstein; J Friedland; M Kitt; H A Lyons
Journal:  Isr J Med Sci       Date:  1977-10

Review 5.  Angiotensin-converting enzyme and the regulation of vasoactive peptides.

Authors:  R L Soffer
Journal:  Annu Rev Biochem       Date:  1976       Impact factor: 23.643

6.  Decreased angiotensin-converting enzyme in the adult respiratory distress syndrome.

Authors:  C W Bedrossian; J Woo; W C Miller; D C Cannon
Journal:  Am J Clin Pathol       Date:  1978-08       Impact factor: 2.493

7.  Measurement of carcinoembryonic antigen in patients with bronchogenic carcinoma.

Authors:  P B Dent; P B McCulloch; O Wesley-James; R MacLaren; W Muirhead; C W Dunnett
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

8.  The specificity and nature of serum-angiotensin-converting enzyme (serum ACE) elevations in sarcoidosis.

Authors:  J Lieberman
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

9.  Diagnostic value of serum angiotensin converting enzyme activity in lung diseases.

Authors:  K Ashutosh; J F Keighley
Journal:  Thorax       Date:  1976-10       Impact factor: 9.139

10.  Prognostic value of preoperative carcinoembryonic antigen (CEA) plasma levels in patients with bronchogenic carcinoma.

Authors:  J P Concannon; M H Dalbow; S E Hodgson; J J Headings; E Markopoulos; J Mitchell; W J Cushing; G A Liebler
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

View more
  9 in total

1.  Direct radioimmunoassay of angiotensin-converting enzyme in sera from patients with pulmonary diseases.

Authors:  K Hiwada; Y Inoue; Y Takada; A Hashimoto; H Akutsu; F Kitatani; T Kokubu
Journal:  Lung       Date:  1987       Impact factor: 2.584

Review 2.  Serum angiotensin converting enzyme in pulmonary disease.

Authors:  P K Rohatgi
Journal:  Lung       Date:  1982       Impact factor: 2.584

Review 3.  Angiotensin peptides and lung cancer.

Authors:  Patricia E Gallagher; Katherine Cook; David Soto-Pantoja; Jyotsana Menon; E Ann Tallant
Journal:  Curr Cancer Drug Targets       Date:  2011-05       Impact factor: 3.428

4.  [Angiotensin-converting enzyme activity during cytostatic therapy in patients with primary inoperable bronchial carcinoma].

Authors:  I Heck; N Niederle
Journal:  Klin Wochenschr       Date:  1983-09-15

5.  Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib.

Authors:  Adnan Aydiner; Rumeysa Ciftci; Fatma Sen
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

Review 6.  EXPRESSION OF THE RENIN-ANGIOTENSIN SYSTEM COMPONENTS IN ONCOLOGIC DISEASES.

Authors:  Sergey Dolomatov; Walery Zukow; Nikolay Novikov; Alexandra Markaryan; Elena Eremeeva
Journal:  Acta Clin Croat       Date:  2019-06       Impact factor: 0.780

7.  Tissue ACE phenotyping in lung cancer.

Authors:  Sergei M Danilov; Roman Metzger; Eckhard Klieser; Karl Sotlar; Ilya N Trakht; Joe G N Garcia
Journal:  PLoS One       Date:  2019-12-26       Impact factor: 3.240

Review 8.  Risk of lung cancer and renin-angiotensin blockade: a concise review.

Authors:  Tobias Rachow; Helmut Schiffl; Susanne M Lang
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-24       Impact factor: 4.553

9.  Angiotensin converting enzyme inhibitors and risk of lung cancer: A systematic review and meta-analysis.

Authors:  Mohammed Batais; Turky Almigbal; Khalid Alotaibi; Abdulaziz Alodhayani; Abdullah Alkhushail; Abdulrahman Altheaby; Mashhor Alhantoushi; Saad Alsaad; Sultan Al Dalbhi; Yasser Alghamdi
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.